AIM
AIM ImmunoTech Inc.
About: AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Employees: 23
0
Funds holding %
of 7,302 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
3% less funds holding
Funds holding: 35 [Q4 2024] → 34 (-1) [Q1 2025]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
36% less capital invested
Capital invested by funds: $919K [Q4 2024] → $590K (-$329K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for AIM.
Financial journalist opinion
Based on 4 articles about AIM published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
AIM ImmunoTech Resumes Trading on NYSE American
Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th
Neutral
GlobeNewsWire
1 week ago
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMID) (“AIM” or the “Company”) today announced the United States Patent and Trademark Office has granted U.S. patent No.
Neutral
GlobeNewsWire
1 week ago
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025 Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025
Neutral
GlobeNewsWire
1 week ago
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date.
Neutral
Seeking Alpha
1 month ago
Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript
Aimia Inc. (OTCPK:AIMFF) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Rhys Summerton - Executive Chairman Steven Leonard - President & Chief Financial Officer Conference Call Participants Surinder Thind - Jefferies Brian Morrison - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to Aimia Inc. First Quarter 2025 Results Conference Call. At this time, all lines are in listen-only mode.
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM's drug Ampligen by Pawel Kalinski, MD, PhD, at the recent Annual Meeting of the American Association of Immunologists held May 3-7, 2025, in Honolulu, HI.
Neutral
GlobeNewsWire
2 months ago
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on.
Neutral
GlobeNewsWire
2 months ago
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had suspended trading of the Company's common stock and of its determination to commence delisting proceedings of the Company's common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company's common stock. The Company plans to appeal the determination to the Exchange's Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.
Neutral
Business Wire
2 months ago
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of AIM ImmunoTech Inc. (the “Company”) — ticker symbol AIM — from NYSE American. Trading in the Company's common stock will be suspended immediately. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due.
Neutral
Seeking Alpha
2 months ago
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Charts implemented using Lightweight Charts™